News from Bayer
June 08, 2022
Bayer’s BlueRock Therapeutics establishes European site for cell therapy innovation
May 23, 2022
Not intended for U.S. and UK Media - Late-breaking data from exploratory post hoc analysis of prespecified pooled analysis FIDELITY presented at Heart Failure 2022 of the Heart Failure Association of the European Society of Cardiology (ESC)
New data support renal and cardiovascular benefits of Kerendia™ (finerenone) in patients with and without history of left ventricular hypertrophy and chronic kidney disease and type 2 diabetes
May 19, 2022
Not intended for U.S. and UK Media
Verquvo™ (vericiguat) approved in China to treat patients with chronic heart failure and reduced ejection fraction